Zyn US shipment volume in 2026
Short Answer
Both the model and the market overwhelmingly agree that Zyn US shipment volume in 2026 will be Above 680 million, with only minor residual uncertainty.
1. Market Behavior & Drivers
This market's price has been static since trading began. The probability of US Zyn shipment volume exceeding 680 million cans in 2026 opened at 93.0% and has not moved. All 315 contracts were traded on the first day, with zero subsequent volume. This price action indicates an extremely strong and stable consensus. The price of 93.0% acts as both the floor and ceiling, with no meaningful support or resistance levels established due to the lack of price discovery.
The market's high conviction appears unshaken by recent company disclosures. Philip Morris International reported that Q1 2026 US Zyn shipment volumes decreased by 23.5% year-over-year, totaling approximately 155 million cans. The company attributed this decline to inventory normalization. The stable 93.0% price suggests traders have fully discounted the Q1 shipment dip as a temporary event. The market sentiment is that demand remains strong enough for shipments over the remaining three quarters to push the full-year total comfortably above the 680 million can threshold.
- Since last update (~24h): Model decreased "Above 680 million" by 2.8pp, market unchanged; edge compressed significantly, model-led.
- Both model (-5.6pp) and market (-6.0pp) dropped for "Above 700 million".
- "Above 800 million" probabilities declined for both model (-3.0pp) and market (-3.0pp).
- Zyn US shipment volumes likely exceed 680 million, despite Q1 decline from inventory normalization.
- FDA's June 30, 2026, modified risk authorization is expected to boost H2 volumes.
- Continued production capacity expansion supports sustained Zyn US volume growth.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Outcome | — | — | Insufficient data |
Current Context
ZYN US shipments declined in Q1 2026, while offtake grew. US ZYN shipment volumes decreased by 23.5% year-over-year in Q1 2026, totaling 2.3 billion pouches or approximately 155 million cans [^][^][^]. This reduction stemmed primarily from inventory normalization [^][^][^]. Despite the shipment decline, Nielsen-estimated offtake volumes for ZYN in the US increased by 10% during the same quarter [^][^]. This indicates sustained consumer demand [^][^].
FDA authorized ZYN modified risk claims, drawing criticism. On June 30, 2026, the FDA authorized 20 ZYN nicotine pouch varieties, in 3mg and 6mg strengths, to be marketed with specific modified risk claims [^][^][^]. This approval allows ZYN to state that switching from cigarettes to these products poses lower risks for various tobacco-related diseases [^][^][^]. Health advocates have criticized the FDA's decision due to concerns about potential youth uptake, even with requirements for Swedish Match, a PMI subsidiary, to conduct postmarket surveillance [^][^]. Philip Morris International (PMI) continues investment in the ZYN brand and is preparing for future innovations, including ZYN ULTRA, which remains under FDA review [^][^].
2. Price Chart
Historical Price (Probability)
Outcome probability
Date
3. Market Data
Contract Snapshot
This market resolves "Yes" if Philip Morris International Inc. reports Zyn U.S. shipment volume above 760,000,000 in 2026, as verified by Fiscal.ai; otherwise, it resolves "No." The market closes early if the event occurs, or by March 31, 2028, at 1:00 AM EDT, with payouts projected 30 minutes after closing.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|
Market Discussion
In Q1 2026, U.S. Zyn shipment volumes declined by 23.5% compared to the prior-year period, totaling 155 million cans or 2.3 billion pouches, with Philip Morris management expecting surplus inventory to normalize during that quarter [^][^][^]. Despite this, market sentiment remains mixed following the FDA's grant of Modified Risk Tobacco Product (MRTP) orders for 20 ZYN variants in July 2026, which is viewed as a potential long-term growth catalyst [^][^][^]. Investors are balancing this potential growth against concerns about whether smoke-free product expansion can consistently offset declines in traditional cigarette volumes and high valuation multiples [^][^][^].
4. Trader Dashboard
Trust profile
Event quality8
Poor
5. What is the projected impact of the FDA's June 2026 'modified risk' authorization on Zyn's US shipment volumes for the second half of the year?
| FDA MRTP Authorization Date | June 30, 2026 [^][^] |
|---|---|
| ZYN U.S. Shipment Volume Decline Q1 2026 | 23.5% to 155 million cans [^][^][^] |
| ZYN Offtake Growth Q1 2026 | 10% [^][^][^] |
The FDA's authorization is expected to significantly boost ZYN's U.S. shipments. The Modified Risk Tobacco Product (MRTP) authorization for ZYN, granted on June 30, 2026, allows the products to be marketed with claims that completely switching from cigarettes to ZYN reduces the risk of major smoking-related diseases. This landmark decision marks the first instance of the FDA authorizing nicotine pouches to carry reduced-risk messaging, a factor deemed crucial for future U.S. demand in the second half of 2026 and beyond [^][^].
ZYN's Q1 2026 shipments declined, but authorization could reverse the trend. In the first quarter of 2026, ZYN U.S. shipment volumes experienced a 23.5% decrease, totaling 155 million cans, primarily attributed to anticipated channel inventory normalization and increased competition [^][^][^]. Despite this decrease in shipments, offtake remained positive, growing by 10% during the same period [^][^][^]. Although analysts had initially forecasted a full-year decline in shipment volumes following the Q1 results, industry observers now anticipate the June 2026 MRTP authorization to provide a competitive advantage and help restore shipment momentum in the second half of 2026 by validating the product's profile to consumers [^][^].
6. How does Zyn's market share and volume growth in the US nicotine pouch category compare to its primary competitor, Velo, as of H1 2026?
| Zyn U.S. Volume Share | 55.5% (Q1 2026) [^][^][^][^][^][^] |
|---|---|
| Zyn U.S. Retail Value Share | 61.3% (Q1 2026) [^][^][^][^][^][^] |
| Velo Plus Market Share | Approximately 10% (mid-2026) [^][^] |
Zyn significantly outperformed Velo in U.S. nicotine pouches by H1 2026. As of H1 2026, Zyn maintained its leading position in the U.S. nicotine pouch category, showing stronger market share and growth compared to Velo [^][^][^][^][^][^]. In Q1 2026, Zyn secured a 55.5% U.S. volume share and a 61.3% retail value share, confirming its status as the category leader [^][^][^][^][^][^]. During Q1 2026, Zyn shipped 155 million cans, with an underlying volume of 202 million cans after inventory adjustments [^][^][^][^][^][^]. Despite a 23.5% decline in Q1 2026 shipment volumes compared to Q1 2025, largely attributed to anticipated inventory normalization, Zyn's U.S. offtake volume grew by 10% as estimated by Nielsen [^][^][^][^][^][^][^][^].
Velo's performance data is limited, hindering direct comparison. While Velo appears to be gaining share, specific H1 2026 U.S. shipment volume or market share figures for Velo are not consistently disclosed in accessible primary sources, preventing a precise comparison with Zyn's detailed metrics [^][^][^][^][^][^]. Nonetheless, reports indicate that Velo Plus, a specific product line within Velo, captured approximately 10% market share in the smoke-free nicotine sector by mid-2026 [^][^]. Additionally, a 2026 update from BAT noted that Velo Plus contributed to a 10.4 point increase in total Modern Oral volume share [^][^][^][^][^][^].
7. What specific factors explain the Q1 2026 divergence between Zyn's declining shipment volumes and rising consumer offtake data from Nielsen?
| Zyn Q1 2026 Shipment Volume | Declined 23.5% to 2.3 billion pouches, or 155 million cans [^][^][^] |
|---|---|
| Nielsen Consumer Offtake Volume Q1 2026 | Increased 10% [^][^][^] |
| Surplus Inventory Cleared Q1 2026 | Approximately 25 million cans [^][^] |
Zyn's Q1 2026 shipments diverged significantly from rising consumer demand. In the first quarter of 2026, Zyn experienced a notable divergence between a 23.5% decline in shipment volumes, which reached 155 million cans, and a 10% increase in consumer offtake volumes as estimated by Nielsen [^][^][^]. This discrepancy is primarily attributed to the normalization of downstream channel inventories [^][^][^]. This followed a substantial 40-million-can inventory rebuild that occurred in Q1 2025 [^][^][^]. Philip Morris International management indicated that approximately 25 million cans of surplus inventory from the end of 2025 were largely cleared during Q1 2026, directly impacting the reported shipment figures [^][^].
Additional factors contributed to the decline in Zyn's shipment volumes. Further contributing to the shipment decline was an unfavorable year-over-year promotional comparison [^][^][^][^][^][^]. Promotional activity for Zyn was notably low in the prior year, making current-year comparisons appear weaker [^][^][^][^][^][^]. Assortment and channel mix challenges also likely hindered shipment growth, stemming from limitations such as uneven competitive landscapes and restricted access to all dynamic strength and flavor segments [^][^][^][^][^][^]. Despite the decrease in shipments, the sustained rise in consumer offtake suggests that underlying consumer demand for Zyn continued its growth trajectory, with shipment figures temporarily influenced by inventory adjustments and supply chain timing [^][^][^][^][^][^].
8. What is Philip Morris International's public reporting schedule for the release of Zyn's quarterly US shipment data through the end of 2026?
| Zyn US shipment reporting | Quarterly [^][^][^] |
|---|---|
| Q1 2026 disclosure date | April 22, 2026 [^][^][^][^][^][^] |
| Q2 2026 disclosure date | July 22, 2026 [^] |
Philip Morris International regularly reports Zyn US shipment data quarterly. Philip Morris International (PMI) consistently releases Zyn US shipment volumes for the United States on a quarterly basis, integrating this data into its broader financial and operational results [^][^][^]. These disclosures are typically presented within earnings releases or investor presentations, establishing a consistent schedule for stakeholders to monitor Zyn's market performance and receive operational updates [^][^][^][^][^][^].
Confirmed 2026 Zyn US shipment data release dates exist. Specific disclosure dates have been confirmed for Zyn US shipment data through the third quarter of 2026. The results for Q1 2026 are slated for release on April 22, 2026, followed by the Q2 2026 earnings release on July 22, 2026 [^][^][^][^][^][^][^]. Additionally, the Q3 2026 results are anticipated on October 21, 2026 [^][^][^][^][^][^][^]. While these dates are established, information regarding the exact release dates for Q4 2026 and the full fiscal year 2026 was not comprehensively available in the research [^][^][^][^][^][^]. Prediction markets concerning Zyn US shipment volume in 2026 generally utilize these official PMI reports for resolution, often focusing on the total volume for the year ending December 31, 2026 [^].
9. What production capacity expansions or supply chain adjustments has Philip Morris International announced for Zyn in the US for 2026?
| Aurora plant investment | $600 million [^][^][^][^] |
|---|---|
| Owensboro production change effective | July 6, 2026 [^][^] |
| Zyn shipment volume decline Q1 2026 | 23.5% [^][^][^] |
Philip Morris International is significantly expanding Zyn production capacity in the US. This involves the continued ramp-up of its new $600 million Zyn manufacturing plant in Aurora, Colorado. This facility began partial production in September 2025 and is designed to create 500 jobs by the time it reaches full operation [^][^][^][^].
PMI is adjusting supply chains due to inventory and market conditions. The company announced a production schedule reduction at its Owensboro, Kentucky, facility, shifting operations from a 24/7 to a 24/5 model, effective July 6, 2026 [^][^]. This adjustment was made in response to specific supply chain inventory dynamics and prevailing market conditions. PMI reported a 23.5% decline in Zyn shipment volumes in Q1 2026, which was primarily due to inventory adjustments in the downstream supply chain following an estimated surplus of 25 million cans at the end of 2025 [^][^][^].
10. What Could Change the Odds
Key Catalysts
Philip Morris International reported a 23.5% decrease in Q1 2026 ZYN shipments, totaling 2.3 billion pouches (155 million cans) [^] [^] . Despite this, analysts project U.S. ZYN volumes and sales will grow 21% to 13.8 billion pouches in 2027, following a forecasted 4% decline for the full year 2026 [^]. A major bullish catalyst in 2026 was the U.S. FDA granting Modified Risk Tobacco Product (MRTP) status to 20 ZYN nicotine pouch variants, a first for the category [^][^][^].
Bearish risks for ZYN include FDA scrutiny over youth access to nicotine pouches, regulatory limbo for some product lines, and aggressive competition from products like Altria's On. PLUS in higher-nicotine strength segments [^][^]. Separately, geopolitical developments in the Middle East continue. The US military struck Iran for a second straight day, and Iran retaliated [^]. However, US negotiators have had positive discussions with regional leaders in Qatar [^].
Key Dates & Catalysts
- Expiration: March 31, 2028
- Closes: March 31, 2028
11. Decision-Flipping Events
- Trigger: Philip Morris International reported a 23.5% decrease in Q1 2026 ZYN shipments, totaling 2.3 billion pouches (155 million cans) [^] [^] .
- Trigger: Despite this, analysts project U.S.
- Trigger: ZYN volumes and sales will grow 21% to 13.8 billion pouches in 2027, following a forecasted 4% decline for the full year 2026 [^] .
- Trigger: A major bullish catalyst in 2026 was the U.S.
13. Historical Resolutions
No historical resolution data available for this series.
